Dysadherin: A Novel Oncogenic Molecular Biomarker in Oesophageal Cancer

Alexandros Charalabopoulos* and Theodoros Liakakos

Corresponding Author

Alexandros Charalabopoulos, MD

Consultant Oesophago-Gastric Surgeon, Department of Upper Gastrointestinal Surgery, Regional Oesophagogastric Cancer Centre, Broomfield Hospital, Mid Essex Hospital Services NHS Trust, Chelmsford, England, UK; E-mail: acharalabopoulos@yahoo.com


Alexandros Charalabopoulos, MD, MSc, PhD, MRCS, FRCS1*; Theodoros Liakakos, MD, PhD2

1Department of Upper Gastrointestinal Surgery, Regional Oesophagogastric Cancer Centre, Broomfield Hospital, Mid Essex Hospital Services NHS Trust, Chelmsford, England, UK
2Upper Gastrointestinal Unit, 1st Department of Surgery, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece

Corresponding Author

Alexandros Charalabopoulos, MD

Consultant Oesophago-Gastric Surgeon, Department of Upper Gastrointestinal Surgery, Regional Oesophagogastric Cancer Centre, Broomfield Hospital, Mid Essex Hospital Services NHS Trust, Chelmsford, England, UK; E-mail: acharalabopoulos@yahoo.com

Article History

Received: July 25th, 2017; Accepted: July 27th, 2017; Published: July 31st, 2017

Cite this Article

Charalabopoulos A, Liakakos T. Dysadherin: A novel oncogenic molecular biomarker in oesophageal cancer. Cancer Stud Mol Med Open J. 2017; 3(2): e5-e6. doi: 10.17140/CSMMOJ-3-e005


© 2017 Charalabopoulos A. This is an open access article distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Dysadherin or FXYD5 is a transmembrane glycoprotein, identified for the first time in 2002 by a team of Japanese researchers.1 Although, it is generally accepted that most of its action is derived from the increased maximal velocity (Vmax) of the Na+ -K+ -ATPase that promotes, there are several actions of dysadherin that cannot be attributed to its interaction with the Na+ -K+ -ATPase.2 Dysadherin is a well-described cancer-associated protein and a potential oncogenic molecular target with promising future significances. It has been distinctly shown, in both the cases of in vivo and in vitro studies, that when expressed in malignant tumours, it signifies augmented tumorigenesis with enhanced metastatic potential and haematogenous spread and is thus linked to poor prognosis.3,4 On the contrary, studies based on human cancer cell lines have demonstrated that introduction of small interfering RNA (siRNA) against dysadherin leads to downregulation and subsequent membranous underexpression of dysadherin, instigating accordingly decreased collective and individual cell motility with subsequent inhibition of tumour aggressiveness and metastatic potential.5 Its main interaction in carcinogenesis takes place with E-cadherin (epithelial cadherin); the most important adhesion molecules of the cadherin family. E-cadherin is involved in cancer development in more than 90% of human cancers, as most are carcinomas of epithelial origin. E-cadherin mediates homophilic cell-to-cell adhesion and promotes adherence between neighboring epithelial cells; its decreased cellular expression is hence associated with enhanced disconnection and dispersal of epithelial cells, promoting cell detachment from the primary lesion and consequently exhibiting increased metastatic potential.

Dysadherin and its closely related E-cadherin, has been studied in various cancers and its correlation with cancer aggressiveness and poor prognosis has been collectively and undoubtedly reported.6,7,8 While the role of dysadherin in gastric cancer has been studied in detail, in oesophageal cancer its role remains mainly unexplored.7,9,10 In a clinical study from Shimada et at11 expression of dysadherin was studied in 117 patients with oesophageal squamous cell carcinoma of all stages. The correlation between immunohistochemically evaluated dysadherin expression with patient clinicopathological data was studied. Oesophageal tumours with expression of dysadherin, displayed worse prognosis in comparison to tumours negative for dysadherin. When dysadherin positivity was combined with absence of E-cadherin expression, a statistically significant detrimental effect was exhibited in that patient group, revealing the worst prognosis of all patient groups. In the group of oesophageal tumours expressing both dysadherin and E-cadherin, prognosis was slightly better, but still poorer compared to the group of tumours that displayed no dysadherin expression. In accordance to what has been shown in relevant studies exploring the role of dysadherin in extraoesophageal human cancers, multivariate analysis revealed that in squamous cell carcinomas of the oesophagus, although expression of E-cadherin is not an independent prognostic factor, expression of dysadherin is (p<0.05).6,11 At present and in contrary to E-cadherin, there is no research investigating the association of dysadherin with oesophageal adenocarcinoma.12 This is particularly important in the West, where adenocarcinoma subtype comprises more than 80% of oesophageal cancers.

Further research is needed in order to explore the role of this promising oncogenic molecular biomarker in oesophageal carcinomas. Dysadherin plays a pivotal role in the carcinogenic process and can therefore become a target of novel oncological agents in an attempt to arrest disease progression and metastasis with obvious implications in prognosis and long-term survival.


The authors declare that they have no conflicts of interest.

1. Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S. Dysadherin, a cancer-associated cell membrane glycoprotein, downregulates E-cadherin and promotes metastasis. Proc Natl Acad Sci U S A. 2002; 99(1): 365-370. doi: 10.1073/pnas.012425299

2. Lubarski I, Karlish SJD, Garty H. Structural and functional interactions between FXYD5 and the Na+-K+-ATPase. Am J Physiol Renal Physiol. 2007; 293: F1818-F1826. doi: 10.1152/ajprenal.00367.2007

3. Lee YK, Lee SY, Park JR, et al. Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation. Cancer Sci. 2012; 103: 1280-1289. doi: 10.1111/j.1349-7006.2012.02302.x

4. Nam JS, Hirohashi S, Wakefield LM. Dysadherin: A new player in cancer progression. Cancer Lett. 2007; 255(2): 161-169. doi: 10.1016/j.canlet.2007.02.018

5. Shimamura T, Yasuda J, Ino Y, et al. Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells. Cancer Res. 2004; 64: 6989-6995. doi: 10.1158/0008-5472.CAN-04-1166

6. Batistatou A, Charalabopoulos AK, Scopa CD, et al. Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Virchows Arch. 2006; 448(6): 763-767. doi: 10.1007/s00428-006-0183-8

7. Shimada Y, Yamasaki S, Hashimoto Y, et al. Clinical significance of dysadherin expression in gastric cancer patients. Clin Cancer Res. 2004; 10(8): 2818-2823. doi: 10.1158/1078-0432.CCR-0633-03

8. Raman P, Purwin T, Pestell R, Tozeren A. FXYD5 is a marker for poor prognosis and a potential driver for metastasis in ovarian carcinomas. Cancer Inform. 2015; 14: 113-119. doi: 10.4137/CIN.S30565

9. Maehata Y, Hirahashi M, Aishima S, et al. Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion. Hum Pathol. 2011; 42(4): 558-567. doi: 10.1016/j.humpath.2010.08.016

10. Yanagihara K, Tanaka H, Takigahira M, et al. Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. Cancer Sci. 2004; 95(7): 575-582. doi: 10.1111/j.1349-7006.2004.tb02489.x

11. Shimada Y, Hashimoto Y, Kan T, et al. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology. 2004; 67(1): 73-80. doi: 10.1159/000080289

12. Charalabopoulos A, Golias C. E-cadherin expression in Barrett’s esophagus and esophageal carcinoma. Esophagus. 2014; 11: 153-161. doi: 10.1007/s10388-014-0424-x


ROTEM Illustration

Rotational Thromboelastometry: Enhancing Hemostasis Monitoring in Anesthesia

Girishkumar Modi*, Vijay Kumar and Nagaraju Munagala


Examining the Rise of Intimate Partner Violence during COVID-19: A Call to Action for Psychologists as Social Advocates

Miranda Landfield, Naqsh Ali, Shahrzad Azarafza, Shelly Baer, Anushree Belur, Naomi Griffin, Dilara Kosak, Jennifer Lerch, Rose Patatanian, Elizabeth Quintero, Stephanie Scott, Guy Balice* and Melia Leibert


Effect of Rhodiola Rosea Supplement on Exhaustive Swimming Test and Physical Fatigue in Male Institute of Cancer Research Mice

Wan-Li Chu, Mon-Chine Lee, Yi-Ju Hsu, Chi-Chang Huang and Yu-Jou Chien*


Safety and Efficacy of Biweekly Gemcitabine in Combination with Capecitabine in Elderly and Frail Patients with Resected Pancreatic Cancer

Muhammad W. Saif*, Nausheen Hakim, Jeffrey Chi, Hasan Rehman, William Nealon, Antonia Maloney, Melissa H. Smith and Jyothi Jose


Liver-Directed Therapy and Systemic Chemotherapy for Pancreatic Adenocarcinoma with Liver Metastases: Experience of 12-years

Muhammad W. Saif*, Shreya P. Goyal, Antonia Maloney, Melissa H. Smith and Jyothi Jose


Mucormycosis in COVID-19 Pandemic

Safa Nefzaoui, Nadia Romdhane, Hela Farjallah*, Imen Zoghlami, Inès Hariga and Chiraz M. Chaouch


Surgical Treatment of Sternal Fracture: Case Report and Literature Review.

Surgical Treatment of Sternal Fracture: Case Report and Literature Review

Jorge Pérez-Acosta, Orlando Téllez-Almenares*, Justo Escalona-Cartaya, Raúl Calas-Balbuena and Olga M. Moreira-Barinaga